Subject characteristics
| Characteristic | ALS-S Group* | ALS-U Group | ALS-T Group | HC Group |
|---|---|---|---|---|
| Number | 14 | 10 | 8 | 14 |
| Male-to-female ratio | 9:5 | 7:3 | 5:3 | 8:6 |
| Age, y* | 64.0 ± 11.8 | 63.9 ± 12.7 | 68.4 ± 9.8 | 58.0 ± 15.9 |
| Disease duration, mo* | 25.8 ± 16.6 | 26.4 ± 19.6 | 28.4 ± 14.7 | Not applicable |
| Baseline NAA/Cr ratio* | ||||
| PrCG | 2.29 ± 0.21† | 2.29 ± 0.21‡ | 2.23 ± 0.19† | 2.52 ± 0.19 |
| PoCG | 2.30 ± 0.25 | 2.33 ± 0.26 | 2.24 ± 0.21‡ | 2.42 ± 0.17 |
| Par | 2.38 ± 0.27 | 2.30 ± 0.26 | 2.44 ± 0.24 | 2.45 ± 0.23 |
| SMA | 2.26 ± 0.27 | 2.26 ± 0.29 | 2.24 ± 0.21 | 2.37 ± 0.20 |
| PMC | 2.50 ± 0.20 | 2.54 ± 0.20 | 2.51 ± 0.16 | 2.59 ± 0.24 |
Note.—ALS-S indicates all subjects with ALS; ALS-T, treated subjects with ALS subjects; ALS-U, untreated subjects with ALS; HC, healthy control subjects; Par, superior parietal lobule; PoCG, postcentral gyrus; PMC, premotor cortex; PrCG, precentral gyrus; and SMA, supplementary motor area.
* Values are expressed as the mean ± SD.
† P < .01 compared with the value in the HC group.
‡ P < .05 compared with the value in the HC group.